Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d lxpression

Journal of Infectious Diseases

Volumn 204, Issue 12, 2011, Pages 1893-1901

  Banovic, Tatjana ^a,b   Yanilla, Mayonelo ^c   Simmons, Russell ^d   Robertson, Ian ^c   Schroder, Wayne A ^a   Raffelt, Neil C ^a   Wilson, Yana A ^a   Hill, Geoffrey R ^a   Hogan, Patrick ^b   Nourse, Clare B ^c,e  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c MATER CHILDREN S HOSPITAL   (Australia)

^d QUEENSLAND HEALTH   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CD1D ANTIGEN; CHICKENPOX VACCINE; CLINDAMYCIN; FLUCLOXACILLIN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; TOPIRAMATE; VALACICLOVIR; VALPROIC ACID; VARICELLA ZOSTER VACCINE;

ABNORMAL RESPIRATORY SOUND; ANTIGEN EXPRESSION; ARTICLE; BRONCHITIS; CASE REPORT; CELLULAR IMMUNITY; CELLULITIS; CEREBRAL PALSY; CHICKENPOX; CHILD; CYTOMEGALOVIRUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEVER; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; HYPOTHERMIA; INVARIANT NATURAL KILLER T CELL; IRRITABILITY; KAPOSI VARICELLIFORM ERUPTION; LETHARGY; LYMPHOCYTE COUNT; MALE; NATURAL KILLER T CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OTITIS MEDIA; OXYGEN THERAPY; PENICILLIN ALLERGY; PNEUMONIA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEIZURE; SEQUENCE HOMOLOGY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VARICELLA PNEUMONITIS; VARICELLA ZOSTER VIRUS; VESICULAR RASH; VIRAL GASTROENTERITIS;

ANTIGENS, CD1D; CELL PROLIFERATION; CHICKENPOX; CHICKENPOX VACCINE; CHILD; HERPESVIRUS 3, HUMAN; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE COUNT; MALE; NATURAL KILLER T-CELLS; VACCINATION; VACCINES, ATTENUATED;

EID: 81055133002     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir660     Document Type: Article

References (47)

1. Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis 2008; 197(Suppl 2):S165-9. (Pubitemid 351590166)
2. Jean-Philippe P, Freedman A, Chang MW, et al. Severe varicella caused by varicella-vaccine strain in a child with significant T-cell dysfunction. Pediatrics 2007; 120:e1345-9. (Pubitemid 350085577)
3. Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 2003; 188:954-9. (Pubitemid 37268243)
4. Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 2003; 188:948-53. (Pubitemid 37268242)
5. Arvin AM. Varicella-zoster virus: molecular virology and virus-host interactions. Curr Opin Microbiol 2001; 4:442-9. (Pubitemid 32720526)
6. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD41 and CD4-8-T cells in mice and humans. J Exp Med 1994; 180:1097-106. (Pubitemid 24256622)
7. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha241 CD4-CD8-T cells. J Exp Med 1997; 186:109-20. (Pubitemid 27304853)
8. Porcelli S, Gerdes D, Fertig AM, Balk SP. Human T cells expressing an invariant V alpha 24-J alpha Q TCR alpha are CD4-and heterogeneous with respect to TCR beta expression. Hum Immunol 1996; 48:63-7. (Pubitemid 26238954)
9. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 2007; 5:405-17. (Pubitemid 46780078)
10. Matsuda JL, KronenbergM. Presentation of self and microbial lipids by CD1 molecules. Curr Opin Immunol 2001; 13:19-25. (Pubitemid 32096955)
11. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278:1626-9. (Pubitemid 27516282)
12. Zlotnik A, Godfrey DI, Fischer M, Suda T. Cytokine production by mature and immature CD4-CD8-T cells: alpha beta-T cell receptor1 CD4-CD8-T cells produce IL-4. J Immunol 1992; 149:1211-5.
13. Lee KA, Kang MH, Lee YS, et al. A distinct subset of natural killer T cells produces IL-17, contributing to airway infiltration of neutrophils but not to airway hyperreactivity. Cell Immunol 2008; 251:50-5.
14. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010; 10:479-89.
15. Grubor-Bauk B, Simmons A, Mayrhofer G, Speck PG. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant V alpha 14-J alpha 281 TCR. J Immunol 2003; 170:1430-4. (Pubitemid 36139511)
16. Grubor-Bauk B, Arthur JL, Mayrhofer G. Importance of NKT cells in resistance to herpes simplex virus, fate of virus-infected neurons, and level of latency in mice. J Virol 2008; 82:11073-83.
17. Pasquier B, Yin L, FondanecheMC, et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 2005; 201:695-701. (Pubitemid 40395115)
18. Rigaud S, Fondaneche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006; 444:110-4. (Pubitemid 44684766)
19. Huck K, Feyen O, Niehues T, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 2009; 119:1350-8.
20. Diana J, Lehuen A. NKT cells: friend or foe during viral infections? Eur J Immunol 2009; 39:3283-91.
21. Loparev VN, Argaw T, Krause PR, Takayama M, Schmid DS. Improved identification and differentiation of varicella-zoster virus (VZV) wildtype strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J Clin Microbiol 2000; 38:3156-60.
22. Ballas ZK, Feldbush TL, Needleman BW, Weiler JM. Complement inhibits immune responses: C3 preparations inhibit the generation of human cytotoxic T lymphocytes. Eur J Immunol 1983; 13:279-84. (Pubitemid 13133349)
23. Ballas ZK, Rasmussen W. Lymphokine-activated killer (LAK) cells. III. Characterization of LAK precursors and susceptible target cells within the murine thymus. J Immunol 1987; 139:3542-9. (Pubitemid 18022013)
24. Ballas ZK, Turner JM, Turner DA, Goetzman EA, Kemp JD. A patient with simultaneous absence of "classical" natural killer cells (CD3-, CD161, and NKH11) and expansion of CD31, CD4-, CD8-, NKH11 subset. J Allergy Clin Immunol 1990; 85:453-9. (Pubitemid 20075182)
25. Matsuda JL, Naidenko OV, Gapin L, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000; 192:741-54.
26. Vazquez M, Shapiro ED. Varicella vaccine and infection with varicellazoster virus. N Engl J Med 2005; 352:439-40.
27. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352:450-8. (Pubitemid 40175971)
28. Seward JF, Marin M, Vazquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 2008; 197(Suppl 2): S82-9. (Pubitemid 351590152)
29. Chaves SS, Haber P, Walton K, et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis 2008; 197(Suppl 2):S170-7. (Pubitemid 351590167)
30. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19:916-23.
31. Lohiya GS, Tan-Figueroa L, Reddy S, Marshall S. Chickenpox and pneumonia following varicella vaccine. Infect Control Hosp Epidemiol 2004; 25:530. (Pubitemid 38954480)
32. Mathieu O, Picot MC, Gelisse P, Breton H, Demoly P, Hillaire-Buys D. Effects of carbamazepine and metabolites on IL-2, IL-5, IL-6, IL-10 and IFN-gamma secretion in epileptic patients: the influence of co-medication. Pharmacol Rep 2011; 63:86-94.
33. Ashrafi M, Hosseini SA, Abolmaali S, et al. Effect of anti-epileptic drugs on serum immunoglobulin levels in children. Acta Neurol Belg 2010; 110:65-70.
34. Basta-Kaim A, Budziszewska B, Leskiewicz M, et al. Effects of new antiepileptic drugs and progabide on the mitogen-induced proliferative activity of mouse splenocytes. Pharmacol Rep 2008; 60:925-32.
35. Liu J, Shaji D, Cho S, Du W, Gervay-Hague J, Brutkiewicz RR. A threonine-based targeting signal in the human CD1d cytoplasmic tail controls its functional expression. J Immunol 2010; 184:4973-81.
36. Sriram V, Willard CA, Liu J, Brutkiewicz RR. Importance of N-linked glycosylation in the functional expression of murine CD1d1. Immunology 2008; 123:272-81.
37. Sanchez DJ, Gumperz JE, Ganem D. Regulation of CD1d expression and function by a herpesvirus infection. J Clin Invest 2005; 115: 1369-78. (Pubitemid 40629057)
38. Marsh RA, Villanueva J, Kim MO, et al. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol 2009; 132:116-23.
39. Ashkar AA, Rosenthal KL. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol 2003; 77:10168-71. (Pubitemid 37122101)
40. White GP, Watt PM, Holt BJ, Holt PG. Differential patterns of methylation of the IFN-gamma promoter at CpG and non-CpG sites underlie differences in IFN-gamma gene expression between human neonatal and adult CD45RO-T cells. J Immunol 2002; 168:2820-7. (Pubitemid 34211661)
41. Veillette A, Dong Z, Latour S. Consequence of the SLAM-SAP signaling pathway in innate-like and conventional lymphocytes. Immunity 2007; 27:698-710. (Pubitemid 350102266)
42. Matangkasombut P, Pichavant M, Saez DE, et al. Lack of iNKT cells in patients with combined immune deficiency due to hypomorphic RAG mutations. Blood 2008; 111:271-4.
43. Locci M, Draghici E, Marangoni F, et al. The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med 2009; 206:735-42.
44. Fulcher DA, Avery DT, Fewings NL, et al. Invariant natural killer (iNK) T cell deficiency in patients with common variable immunodeficiency. Clin Exp Immunol 2009; 157:365-9.
45. Lindh E, Rosmaraki E, Berg L, et al. AIRE deficiency leads to impaired iNKT cell development. J Autoimmun 2010; 34:66-72.
46. Ng WF, Tudhope SJ, von Delwig A, Lilic D. Invariant natural killer T (iNKT) cell deficiency in chronic mucocutaneous candidiasisda consequence or a cause? Immunol Lett 2011; 135:180-3.
47. Gershon AA. Varicella vaccine: rare serious problemsdbut the benefits still outweigh the risks. J Infect Dis 2003; 188:945-7. (Pubitemid 37268241)